Kering Eyewear Reports Rise in Revenue for Full Year 2024, While Total Kering Group Revenue Declines

By Staff
Wednesday, February 12, 2025 12:24 AM PARIS—Kering Eyewear, part of the global luxury group Kering (KER.PA), has reported revenue of €1.6 billion for the full year 2024, up 6 percent on a year-over-year comparable basis. In the fourth quarter, sales totaled €326 million, an increase of 8 percent as reported and up 7 percent on a comparable basis, driven by all regions as well as the main brands in its portfolio, according to the company. The Kering Group, however, reported a 12 percent decline in overall revenue in 2024.

Bausch + Lomb Ends Third-Party Sales Process; Continues Pursuit of Separation From Bausch Health Parent Company

By Staff
Friday, February 7, 2025 12:30 AM VAUGHAN, Ontario—Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company and contact lens maker, announced that it has ended negotiations for a potential sale with a third-party buyer. In December of 2024, as reported in VMAIL, the company said it was exploring a potential sale and other options that would lead to a full separation from parent company Bausch Health Companies Inc. Yesterday, Bausch + Lomb issued the following update on a potential sale, which was disclosed in December following a request from the Canadian Investment Regulatory Organization:

McKesson to Acquire 80 Percent Controlling Interest in PRISM Vision Holdings

By Staff
Thursday, February 6, 2025 12:24 AM IRVING, Texas—McKesson Corporation, a health care services provider, announced that it has signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC, a provider of general ophthalmology and retina management services, from private equity firm Quad-C.

Hoya Reports Revenue Growth for Third Quarter 2024 and Issues Updated Guidance

By Staff
Tuesday, February 4, 2025 12:24 AM TOKYO—Hoya Corporation (7741:Tokyo) has announced consolidated revenue of 220.8 billion yen for the third quarter ending December 31, 2024, up 13 percent from year-ago, and up 11 percent on a constant currency basis. Pretax profit rose to 65.2 billion yen, a 31 percent increase compared with the year-ago period, up 28 percent with the constant currency effect. Operating profit increased 17 percent to 66.1 billion yen compared with the prior-year period, an increase of 13 percent in constant currency, according to Hoya.

EyePromise Is Acquired by PRN Physician Recommended Nutriceuticals

By Staff
Monday, February 3, 2025 12:24 AM CHESTERFIELD, Mo.—EyePromise, a company that provides scientifically supported eye vitamins to support eye health, has announced that it has been acquired by PRN Physician Recommended Nutriceuticals, which partners with ophthalmologists and optometrists to provide patients with evidence-based nutriceuticals to support their long-term ocular health. According to the announcement, the acquisition is effective immediately. The newly combined company will allow both organizations to provide a greater value and service to its partners, the companies said, from practices to patients to suppliers and more.

Inspecs Group Reports Mixed 2024 Preliminary Financial Results

By Staff
Friday, January 31, 2025 12:24 AM BATH, England—Inspecs Group plc, (LSE: SPEC), a global designer, manufacturer and distributor of eyewear, including sunglasses, optical frames, lenses and low vision products, has announced full-year preliminary financial results for the year ended December 31, 2024. Group revenue for 2024 declined slightly to £200.5 million compared with £203.3 million in 2023. However, the company also reported improved gross margins and reduced debt in 2024, as well as a revenue increase of 5.9 percent in the second half of the year.

Safilo Group Reports Preliminary Net Sales Loss of 2.3 Percent for Full Year 2024

By Staff
Wednesday, January 29, 2025 12:24 AM PADUA, Italy—Safilo Group S.p.A. (SFLG.MI) has reported preliminary key performance indicators for the financial year ended December 31, 2024. In 2024, Safilo's preliminary net sales amounted to €993.2 million, a decrease of 2.3 percent at constant exchange rates and 3.1 percent at current exchange rates compared with 2023. According to the company, the decline is due to the end of the Jimmy Choo license. Net of this impact, the trend in sales was slightly positive, the company stated, driven by the resilience of the European business. The North American market declined, however, marked by the disappointing performance of sunglasses and the sports business.

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding to Support OK-101 Drug Candidate

By Staff
Monday, January 27, 2025 12:15 AM LONDON and NEW YORK—OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing therapies for the treatment of neuropathic corneal pain (NCP), and for inflammatory dry eye disease (DED), has announced that it has received $1.4 million in non-dilutive funding.

NovaBay Pharmaceuticals Completes the Sale of its Avenova Eyecare Business to PRN, Seeks Full Company Dissolution

By Staff
Friday, January 24, 2025 12:24 AM EMERYVILLE, Calif.—NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a developer of eyecare, skin care and wound care products, has announced the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC (PRN) for $11.5 million. The transaction represents substantially all of the assets of the company, according to the announcement. The company said it is now seeking stockholder approval for Proposal Two, which would authorize the company's complete liquidation and dissolution.

VSP Vision Completes the Acquisition of Eyemart Express

By Staff
Thursday, January 23, 2025 12:24 AM RANCHO CORDOVA, Calif.—VSP Vision announced that it has completed the acquisition of national optical retailer Eyemart Express from FFL Partners and Leonard Green & Partners. As reported in VMAIL, the companies first entered into a definitive agreement in October of 2024. “This purposeful investment offers our clients and members more network choice and will help meet patient needs in rural and underserved communities,” said VSP Vision president and CEO Michael Guyette.

Johnson & Johnson Reports Fourth Quarter and Full Year 2024 Sales Increase and Forecasts 2025 Growth

By Staff
Thursday, January 23, 2025 12:21 AM NEW BRUNSWICK, N.J.—Johnson & Johnson announced results for its fourth-quarter and full year 2024. The company reported 2024 fourth-quarter sales growth of 5.3 percent to $22.5 billion with operational growth of 6.7 percent and adjusted operational growth of 5.7 percent.

KITS Eyecare Shares Preliminary Fourth Quarter and Full Year 2024 Results, Reports Revenue Growth

By Staff
Wednesday, January 22, 2025 12:21 AM VANCOUVER, British Columbia—KITS Eyecare Ltd., a vertically integrated eyecare provider, has reported selected preliminary unaudited results for its fourth quarter and full year ended December 31, 2024. In Q4, the company reported total revenue growth of 42 percent year-over-year to approximately $44.8 million.

National Vision Announces Leadership Changes, Forecasts 2024 Fourth Quarter and Full-Year Revenue Growth

By Staff
Thursday, January 16, 2025 5:30 PM DULUTH, Ga.—National Vision Holdings, Inc. (NASDAQ: EYE), one of the largest optical retail companies in the United States with more than 1,200 stores in 38 states and Puerto Rico, has announced updates to its leadership structure that include expanded responsibilities for three executive team members and that Melissa Rasmussen, chief financial officer, will depart following a transition period. According to the announcement, Rasmussen will be departing the company to pursue an opportunity in another industry. She intends to continue in her role through the release of the company’s fourth quarter and full fiscal year 2024 financial results which is expected to occur on February 26, 2025.

Sight Sciences Forecasts Moderate Revenue Growth in 2024 Fourth Quarter, Decreased Growth for 2024 Full Year

By Staff
Thursday, January 16, 2025 12:18 AM MENLO PARK, Calif.—Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, has reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024.

RxSight Projects Surge in Revenue Growth for 2024 Fourth Quarter and Full Year, Increases Guidance for 2025

By Staff
Thursday, January 16, 2025 12:15 AM ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company providing customized vision to patients following cataract surgery, has announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. Preliminary unaudited fourth quarter 2024 revenue is expected to be approximately $40.2 million, the company reported, representing growth of approximately 41 percent compared with the prior-year period. Preliminary unaudited 2024 fiscal year revenue is expected to be approximately $139.9 million, representing growth of approximately 57 percent compared with the prior year.